JAMA Network Home
Sign In
Research Letter

Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines

JAMA 10.1001/jama.2025.13917

September 03, 2025 at 11:00 AM EDT

Read the full article

This study assesses the reporting by journal publications and National Comprehensive Cancer Network (NCCN) guidelines of clinical uncertainties identified by the US Food and Drug Administration’s (FDA) Benefit-Risk Framework pertaining to cancer drugs approved in 2019-2022.

Corresponding Author: Avi Cherla, MSc, Department of Health Policy, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, United Kingdom (a.j.cherla@lse.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13917?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090325

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks